Member Info for Del786

300,000 share buy

Cosmo Adamo, VP, Service, BrandsMart USA, said "BrandsMart extended its contract with ServicePower because we've seen real improvement in our field service operation using the technology. We've increased the productivity of our mobile technicians. Technicians arrive quickly and when promised, and get the job finished in the same visit. We also have seen real benefits with ServiceOperations. Using ServiceOperations, we were able to automate warranty claims processing, taking the knowledge about each individual manufacturer or third party administrator's process and setting it up within ServiceOperations. We send all claims through ServiceOperation which directly process claims for its own client manufacturers and administrators, or forwards those not in its ecosystem on to external claims processors. 100% of warranty claims are now submitted, in a timely manner, with correct and complete information, to the appropriate processor, resulting in very high reimbursement rates for BrandsMart. Overall, ServicePower's mobile workforce management solution has helped BrandsMart achieve increased productivity, better warranty claims submission and reimbursement rates, reduced costs, and increased customer satisfaction rates. We look forward to increased ROI in the future."

ServicePower Technologies Plc (AIM: SVR), a market leader in mobile workforce management software, today announces that it has signed a contract with leading global insurer for ServicePower Unity, ServicePower's complete software platform; a deal valued at nearly $1,000,000 over the next five years.

Looking at previous RNS...think they will pay many multiples to buy svr.. Buys showing as red trades...

Operational Highlights · Following the momentum gained in 2015, 11 deals were signed during the period with new and existing customers, with a strong pipeline in place for H2 2016 and 2017 · The Company entered into a number of strategic partnerships in order to broaden its functional capabilities and cloud-based offerings, sales and implementation capacity · Continued investment in product innovation · The management remains confident in the strategy and outlook for the business Post Period end · Positive EBITDA and net income achieved in June, July and August 2016 with the increase in revenue and cost efficiencies · Signing of contracts worth more than £1 million of annual revenue · Multiple new customers and products went live

Financial Highlights Trading for the half-year is in line with management expectations · Total revenues of £6.4 million (H1 2015: £6.9 million) o Recurring revenues accounted for 98% o Product revenues comprising 66% · Gross profit of £3.3 million (H1 2015: £3.4 million) · Loss before tax of £0.7 million (H1 2015: £0.6 million) · Cash balance at 30 June 2016 was £0.7 million (30 June 2015 Cash balance: £0.7 million) o The Company anticipates a significant improvement in the Company's cash position in H2 2016 with increased revenue trends and support contract renewals

A quick look at previous RNS & contract wins...the offer could be many multiples of current price. Low shares in issue..

Funding Oxford Pharmascience remains well-funded to complete this next stage of work on clinical development and the regulatory pathway for its OXPzeroTM products, as well as the development work on atorvastatin, with cash balances as at 31 October 2016 of circa £22.6 million. Commenting on the progress, CEO Marcelo Bravo said: "In parallel to the ongoing commercial partnering activities, we are pleased to see OXPzeroTM Ibuprofen going back into the clinic and our OXPzeroTM NSAIDs IP protection being strengthened. We look forward to receiving advice from the FDA on our over-the-counter and prescription OXPzeroTM Ibuprofen product development strategies."

Marcelo Bravo, Chief Executive Officer, commented: "During the period we have made good progress in commercialisation discussions regarding our lead assets, OXPzero™ Ibuprofen and OXPzero Naproxen™, and our continuing focus remains to progress these to market. We are making significant progress advancing the OXPzeroTM technology through the improvement of the drug release characteristics, scale-up and optimization of the manufacturing process and through additional patent applications to strengthen the IP. "We plan to clarify the regulatory pathway for product approval in the US and alongside this we have expanded our business development efforts, with a focus on the Rx market and on the taste-masking applications of our technology in the OTC market where we are in ongoing partnership discussions. While it is now clear that a major licensing deal will take longer to generate, our OXPzeroTM NSAIDs have the potential to offer meaningful advantages versus standard ibuprofen and naproxen, both in terms of the improved gastrointestinal (GI) safety profile and taste-masking, and we continue to believe there are significant, disruptive and valuable opportunities in the $12bn global NSAIDs market. "We will update shareholders in due course on our commercial discussions and wider development plans."

Some sellers flushed out...

Yup, volume is great. Expecting a few more delayed buys to appear

1 million shares

Is great. Buys outweigh sells, expecting a big blue day

expecting this to pick up, only a few sellers- a good sign. Expecting some large trades..

Share buy. Look at them chunky buys..

MMS - Moving on buys..

Paying above ask.. tick up coming. Could see a big blue day..

Current Market Cap VS Cash in the bank ... no brainer

Financial Highlights Net Asset Value During the six-month period ended 31 December 2015, the net asset value ("NAV") of the Company reduced to £26.3 million (10.5p per Share) from £26.6 million (10.6p per Share) at 30 June 2015 and £37.8 million (15.1p per Share) at 31 December 2014. The change in NAV during the first half of the financial year was caused mainly by a reduction in the fair value of the private equity portfolio of £3.5 million and an increase of £3.4 million (1.4p per Share) in the cash balances held. The value of other liabilities increased by £0.2 million. These aggregate changes mask a material change in the structure of the Company's income statement and balance sheet, which are explained in more detail below. Cash At 31 December 2015, the Company's cash balances increased to £13.2 million (5.3p per Share) from £9.8 million (3.9p per Share) at 30 June 2015 and £4.9 million (1.9p per Share) at 31 December 2014. The principal sources of cash during the period were from Elements Markets LLC ("Element Markets") and TEP (Solar Holdings) Limited ("TEP Solar"). Subsequent to period-end, cash held by TEP (Renewables Holding) Limited ("TEP Renewables") was paid to the Company. At the time of writing, TEP holds cash of approximately £17.6 million (7.1p per Share). Great volume today, 9 X 4.9 k buys today.. Perhaps some news soon

Loads of buyers